ArticleJournal of Alzheimer's disease : JAD2017
Diabetes is Not Associated with Alzheimer's Disease Neuropathology.
Article in Journal of Alzheimer's disease : JAD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 76 citations in OpenAlex.
- Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications.The journal of prevention of Alzheimer's disease · 2026Review
- Article
- Risk Factors, Pathological Changes, and Potential Treatment of Diabetes-Associated Cognitive Dysfunction.Journal of diabetes · 2025Review
- Review of Associations of Diabetes and Insulin Resistance With Brain Health in Three Harmonised Cohort Studies of Ageing and Dementia.Diabetes/metabolism research and reviews · 2025Review
- Systemic determinants of brain health in ageing.Nature reviews. Neurology · 2024Review
- Alzheimer's Disease, Obesity, and Type 2 Diabetes: Focus on Common Neuroglial Dysfunctions (Critical Review and New Data on Human Brain and Models).Brain sciences · 2024Review
- Characterizing cognitive phenotypes and clinical correlates in type 2 diabetes using fuzzy clustering and decision tree analysis.Scientific reports · 2024Article
- Exploratory Dual PET imaging of [Bioorganic & medicinal chemistry letters · 2024Article
- Diabetes-related clinical and microstructural white matter changes in patients with Alzheimer's disease.Brain and behavior · 2024Article
- Metformin, age-related cognitive decline, and brain pathology.Neurobiology of aging · 2024Article
- Diabetes: a tipping point in neurodegenerative diseases.Trends in molecular medicine · 2023Review
- Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and ExtendPharmaceuticals (Basel, Switzerland) · 2023Article
- Prediction of neuropathologic lesions from clinical data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Dementia in Diabetes: The Role of Hypoglycemia.International journal of molecular sciences · 2023Review
- The gut microbiota-astrocyte axis: Implications for type 2 diabetic cognitive dysfunction.CNS neuroscience & therapeutics · 2023Review
- Cardiovascular Risk Factors and Risk of Alzheimer Disease and Mortality: A Latent Class Approach.Journal of the American Heart Association · 2023Article
- Prevailing Antagonistic Risks in Pleiotropic Associations with Alzheimer's Disease and Diabetes.Journal of Alzheimer's disease : JAD · 2023Article
- Potential mechanisms to modify impaired glucose metabolism in neurodegenerative disorders.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Review
- Impaired Early Insulin Response to Glucose Load Predicts Episodic Memory Decline: A 10-Year Population-Based Cohort Follow-Up of 45-74-Year-Old Men and Women.Journal of Alzheimer's disease : JAD · 2023Article
- Cognition and BDNF levels in prediabetes and diabetes: A mediation analysis of a cross-sectional study.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundPrevious evidence linking diabetes to Alzheimer's disease (AD) neuropathology is mixed and scant data are available from low- and middle-income countries.
objectiveTo investigate the association between diabetes and AD neuropathology in a large autopsy study of older Brazilian adults.
methodsIn this cross-sectional study, diabetes was defined by diagnosis during life or use of antidiabetic medication. A standardized neuropathological examination was performed using immunohistochemistry. The associations of diabetes with Consortium to Establish and Registry for Alzheimer Disease (CERAD) scores for neuritic plaques and Braak-Braak (BB) scores for neurofibrillary tangles were investigated using multivariable ordinal logistic regression. We investigated effect modification of education, race, and APOE on these associations.
resultsAmong 1,037 subjects (mean age = 74.4±11.5 y; mean education = 4.0±3.7 y; 48% male, 61% White), diabetes was present in 279 subjects. Diabetes was not associated with BB (OR = 1.12, 95% CI = 0.81-1.54, p = 0.48) or with CERAD (OR = 0.97, 95% CI = 0.68-1.38, p = 0.86) scores on analyses adjusted for sociodemographic and clinical variables. We observed effect modification by the APOE allele ɛ4 on the association between diabetes mellitus and BB scores.
conclusionNo evidence of an association between diabetes and AD neuropathology was found in a large sample of Brazilians; however, certain subgroups, such as APOE allele ɛ4 carriers, had higher odds of accumulation of neurofibrillary tangles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.